Joy Goudie - Daxor Independent Director
| DXR Stock | USD 9.89 0.61 6.57% |
Insider
Joy Goudie is Independent Director of Daxor since 2020.
| Tenure | 4 years |
| Address | 109 Meco Lane, Oak Ridge, TN, United States, 37830 |
| Phone | 212 330 8500 |
| Web | https://www.daxor.com |
Joy Goudie Latest Insider Activity
Tracking and analyzing the buying and selling activities of Joy Goudie against Daxor stock is an integral part of due diligence when investing in Daxor. Joy Goudie insider activity provides valuable insight into whether Daxor is net buyers or sellers over its current business cycle. Note, Daxor insiders must abide by specific rules, including filing SEC forms every time they buy or sell Daxor'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Joy Goudie over two weeks ago Acquisition by Joy Goudie of 2500 shares of Daxor at 9.88 subject to Rule 16b-3 |
Daxor Management Efficiency
The company has Return on Asset of (0.014) % which means that on every $100 spent on assets, it lost $0.014. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0535 %, implying that it generated $0.0535 on every 100 dollars invested. Daxor's management efficiency ratios could be used to measure how well Daxor manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Daxor's Return On Tangible Assets are relatively stable compared to the past year. As of 11/26/2024, Return On Assets is likely to grow to 0.01, though Return On Capital Employed is likely to grow to (0). At this time, Daxor's Total Assets are relatively stable compared to the past year. As of 11/26/2024, Return On Tangible Assets is likely to grow to 0.01, while Non Currrent Assets Other are likely to drop (36.6 M).Similar Executives
| Showing other executives | INSIDER Age | ||
| Keisha Harcum | Milestone Scientific | N/A | |
| Josh Bennett | Repro Med Systems | N/A | |
| Jeannine Sheehan | InfuSystems Holdings | 48 | |
| Tom Adams | Repro Med Systems | N/A | |
| Brian Case | Repro Med Systems | 51 | |
| BSN MBA | InfuSystems Holdings | 45 | |
| Thomas Ruiz | InfuSystems Holdings | 66 | |
| John Hargraves | Precision Optics, | N/A | |
| Donald Major | Precision Optics, | 63 | |
| Daniel Habhegger | Precision Optics, | 54 | |
| Wang Xin | Meihua International Medical | 35 | |
| Richard Forkey | Precision Optics, | 84 | |
| Richard Cyr | Precision Optics, | N/A | |
| Lianzhang Zhao | Meihua International Medical | 56 | |
| Yulin Wang | Meihua International Medical | 55 | |
| Joseph Forkey | Precision Optics, | 56 | |
Management Performance
| Return On Equity | 0.0535 | ||||
| Return On Asset | -0.014 |
Daxor Leadership Team
Elected by the shareholders, the Daxor's board of directors comprises two types of representatives: Daxor inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Daxor. The board's role is to monitor Daxor's management team and ensure that shareholders' interests are well served. Daxor's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Daxor's outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, Chief CFO | ||
| James Lombard, Independent Director | ||
| Michael Feldschuh, Interim CEO, Interim President, Head of Bus. Devel. and Strategic Initiatives and Director | ||
| Joy Goudie, Independent Director | ||
| Jean Oertel, Senior Experience | ||
| Bernhard Saxe, Independent Director | ||
| Guido Manzo, Vice Sales | ||
| Robert Michel, Chief Financial Officer | ||
| Henry Cremisi, Director | ||
| Kathryn Kornafel, Senior Development | ||
| Robert Willens, Independent Director | ||
| Jonathan Feldschuh, Chief Scientific Officer, Director | ||
| FACC MBA, Chief Officer | ||
| Martin Wolpoff, Independent Director | ||
| Edward Feuer, Director | ||
| Linda Cooper, Vice Operations |
Daxor Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Daxor a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0535 | ||||
| Return On Asset | -0.014 | ||||
| Profit Margin | 10.94 % | ||||
| Operating Margin | (4.19) % | ||||
| Current Valuation | 42.93 M | ||||
| Shares Outstanding | 4.84 M | ||||
| Shares Owned By Insiders | 56.51 % | ||||
| Shares Owned By Institutions | 2.00 % | ||||
| Number Of Shares Shorted | 12.64 K | ||||
| Price To Earning | 10.77 X |
Pair Trading with Daxor
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Daxor position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Daxor will appreciate offsetting losses from the drop in the long position's value.Moving against Daxor Stock
The ability to find closely correlated positions to Daxor could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Daxor when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Daxor - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Daxor to buy it.
The correlation of Daxor is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Daxor moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Daxor moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Daxor can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Daxor Stock Analysis
When running Daxor's price analysis, check to measure Daxor's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Daxor is operating at the current time. Most of Daxor's value examination focuses on studying past and present price action to predict the probability of Daxor's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Daxor's price. Additionally, you may evaluate how the addition of Daxor to your portfolios can decrease your overall portfolio volatility.